Peplin Inc.’s Positive Phase IIb AK Trial Result Details
EMERYVILLE, Calif. & BRISBANE, Australia--(BUSINESS WIRE)--Peplin, Inc. (ASX:PLI) today announced further results of its Phase IIb actinic (solar) keratosis (AK) Australian and US trial for lesions on the head, which comprise face and scalp, and the selection of a Phase III dose for its lead product candidate PEP005 (ingenol mebutate) Gel.